| Skylar Alsop, MD | |
|
4401 Harrison Blvd, Ogden, UT 84403-3195 | |
| (717) 919-8393 | |
| Not Available |
| Full Name | Skylar Alsop |
|---|---|
| Gender | Male |
| Speciality | Pathology |
| Experience | 19 Years |
| Location | 4401 Harrison Blvd, Ogden, Utah |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114133584 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mckay Dee Hospital | Ogden, UT | Hospital |
| Layton Hospital | Layton, UT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Intermountain Healthcare Services, Inc | 1850209420 | 3063 |
News Archive
University of Florida radiation oncologists are using a sophisticated medical device to treat patients who have recent diagnoses of metastatic cancer, where the disease has started to spread from one part of the body to another.
Virginia Commonwealth University researchers have discovered, in theory, the possibility of creating large, hollow magnetic cage molecules that could one day be used in medicine as a drug delivery system to non-invasively treat tumors, and in other emerging technologies.
Hepatocyte growth factor gene therapy could be used to treat patients with severe peripheral arterial disease, suggest results of a phase I clinical trial.
Among patients scheduled for a percutaneous coronary intervention (PCI; procedures such as balloon angioplasty or stent placement used to open narrowed coronary arteries), pretreatment with the antiplatelet agent clopidogrel was not associated with a lower risk of overall mortality but was associated with a significantly lower risk of major coronary events, according to a review and meta-analysis of previous studies published in the December 19 issue of JAMA.
› Verified 6 days ago
| Entity Name | Ihc Health Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629260880 PECOS PAC ID: 1850209420 Enrollment ID: O20031105000079 |
News Archive
University of Florida radiation oncologists are using a sophisticated medical device to treat patients who have recent diagnoses of metastatic cancer, where the disease has started to spread from one part of the body to another.
Virginia Commonwealth University researchers have discovered, in theory, the possibility of creating large, hollow magnetic cage molecules that could one day be used in medicine as a drug delivery system to non-invasively treat tumors, and in other emerging technologies.
Hepatocyte growth factor gene therapy could be used to treat patients with severe peripheral arterial disease, suggest results of a phase I clinical trial.
Among patients scheduled for a percutaneous coronary intervention (PCI; procedures such as balloon angioplasty or stent placement used to open narrowed coronary arteries), pretreatment with the antiplatelet agent clopidogrel was not associated with a lower risk of overall mortality but was associated with a significantly lower risk of major coronary events, according to a review and meta-analysis of previous studies published in the December 19 issue of JAMA.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Skylar Alsop, MD 614 Blackthorne Ct, Chesapeake, VA 23322-9087 Ph: (717) 919-8393 | Skylar Alsop, MD 4401 Harrison Blvd, Ogden, UT 84403-3195 Ph: (717) 919-8393 |
News Archive
University of Florida radiation oncologists are using a sophisticated medical device to treat patients who have recent diagnoses of metastatic cancer, where the disease has started to spread from one part of the body to another.
Virginia Commonwealth University researchers have discovered, in theory, the possibility of creating large, hollow magnetic cage molecules that could one day be used in medicine as a drug delivery system to non-invasively treat tumors, and in other emerging technologies.
Hepatocyte growth factor gene therapy could be used to treat patients with severe peripheral arterial disease, suggest results of a phase I clinical trial.
Among patients scheduled for a percutaneous coronary intervention (PCI; procedures such as balloon angioplasty or stent placement used to open narrowed coronary arteries), pretreatment with the antiplatelet agent clopidogrel was not associated with a lower risk of overall mortality but was associated with a significantly lower risk of major coronary events, according to a review and meta-analysis of previous studies published in the December 19 issue of JAMA.
› Verified 6 days ago
Norman O Wahlstrom Jr., MD Pathology Medicare: Not Enrolled in Medicare Practice Location: 5475 South 500 East, Ogden, UT 84405 Phone: 801-479-2392 Fax: 801-479-2396 | |
Mark Douglas Orton, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 5475 S 500 E, Ogden, UT 84405 Phone: 801-479-2392 Fax: 801-479-2396 | |
Dr. Riley E Alexander, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 4401 Harrison Blvd, Ogden, UT 84403 Phone: 801-387-2800 | |
Dr. Jan E Woods, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 5475 S 500 E, Ogden, UT 84405 Phone: 801-479-2390 Fax: 801-479-2396 | |
Dr. Paul S Thorpe, MD Pathology Medicare: Not Enrolled in Medicare Practice Location: 4401 Harrison Blvd, Ogden, UT 84403 Phone: 801-387-2800 | |
Dr. Colby Arthur Fernelius, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 5475 S 500 E, Ogden, UT 84405 Phone: 801-479-2390 |